JP2023530231A - 転写増強アソシエートドメイン（ｔｅａｄ）阻害剤及びその使用 - Google Patents

転写増強アソシエートドメイン（ｔｅａｄ）阻害剤及びその使用 Download PDF

Info

Publication number
JP2023530231A
JP2023530231A JP2022574770A JP2022574770A JP2023530231A JP 2023530231 A JP2023530231 A JP 2023530231A JP 2022574770 A JP2022574770 A JP 2022574770A JP 2022574770 A JP2022574770 A JP 2022574770A JP 2023530231 A JP2023530231 A JP 2023530231A
Authority
JP
Japan
Prior art keywords
optionally substituted
formula
ring
compound
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022574770A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530231A5 (enExample
Inventor
ナサニエル・エス・グレイ
ティンフ・ジャン
ニコラス・ポール・クフャトコフスキ
メンヤン・ファン
ジアンウェイ・チェ
ウェンチャオ・ル
Original Assignee
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Publication of JP2023530231A publication Critical patent/JP2023530231A/ja
Publication of JP2023530231A5 publication Critical patent/JP2023530231A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2022574770A 2020-06-03 2021-06-02 転写増強アソシエートドメイン（ｔｅａｄ）阻害剤及びその使用 Withdrawn JP2023530231A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063034248P 2020-06-03 2020-06-03
US63/034,248 2020-06-03
US202163183094P 2021-05-03 2021-05-03
US63/183,094 2021-05-03
PCT/US2021/035343 WO2021247634A1 (en) 2020-06-03 2021-06-02 Inhibitors of transcriptional enhanced associate domain (tead) and uses thereof

Publications (2)

Publication Number Publication Date
JP2023530231A true JP2023530231A (ja) 2023-07-14
JP2023530231A5 JP2023530231A5 (enExample) 2024-06-12

Family

ID=76641834

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022574770A Withdrawn JP2023530231A (ja) 2020-06-03 2021-06-02 転写増強アソシエートドメイン（ｔｅａｄ）阻害剤及びその使用

Country Status (6)

Country Link
US (1) US20240124406A1 (enExample)
EP (1) EP4164752A1 (enExample)
JP (1) JP2023530231A (enExample)
AU (1) AU2021283892A1 (enExample)
CA (1) CA3180846A1 (enExample)
WO (1) WO2021247634A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024513606A (ja) * 2021-04-16 2024-03-26 オリオン コーポレーション Ｔｅａｄ阻害剤
WO2024255856A1 (zh) * 2023-06-14 2024-12-19 赛诺哈勃药业（成都）有限公司 一种调控tead活性的化合物、其制备方法及其用途

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
US11458149B1 (en) 2019-05-31 2022-10-04 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
BR112021024108A2 (pt) 2019-05-31 2022-03-22 Ikena Oncology Inc Inibidores de tead e usos dos mesmos
AR121506A1 (es) 2020-03-03 2022-06-08 Pic Therapeutics Inc Inhibidores del eif4e y sus usos
BR112023014751A2 (pt) * 2021-01-25 2023-10-03 Ikena Oncology Inc Combinação de um inibidor de tead de 3-(imidazol-4-il)-4-(amino)-benzenossulfonamida com um inibidor de egfr e/ou inibidor de mek para uso no tratamento de câncer de pulmão
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
IL310924A (en) 2021-08-25 2024-04-01 Pic Therapeutics Inc Eif4e inhibitors and uses thereof
EP4464693A4 (en) * 2022-01-14 2025-10-29 Daewoong Pharmaceutical Co Ltd NEW AMINOBENZENE DERIVATIVE WITH A CANCER CELL GROWTH INHIBITORY EFFECT, AND PREVENTIVE OR THERAPEUTIC PHARMACEUTICAL COMPOSITION CONTAINING IT AS THE ACTIVE INGREDIENT
WO2023146511A1 (en) * 2022-01-25 2023-08-03 Vivace Therapeutics, Inc. Compounds and methods of use thereof
TWI878871B (zh) * 2022-05-09 2025-04-01 大陸商浙江同源康醫藥股份有限公司 多環類化合物及其用途
CN119968359A (zh) 2022-09-29 2025-05-09 英矽智能科技知识产权有限公司 Tead抑制剂及其使用方法
WO2024088399A1 (zh) * 2022-10-27 2024-05-02 勤浩医药（苏州）有限公司 含磷化合物、药物组合物及其应用
WO2024099435A1 (zh) * 2022-11-10 2024-05-16 武汉人福创新药物研发中心有限公司 Tead抑制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003257666A1 (en) * 2002-08-23 2004-03-11 Kirin Beer Kabushiki Kaisha COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME
CA2747419C (en) * 2009-01-12 2014-07-08 Icagen, Inc. Sulfonamide derivatives
US11186554B2 (en) * 2017-05-03 2021-11-30 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
WO2019040380A1 (en) * 2017-08-21 2019-02-28 Vivace Therapeutics, Inc. BENZOSULFONYL COMPOUNDS
WO2019113236A1 (en) * 2017-12-06 2019-06-13 Vivace Therapeutics, Inc. Benzocarbonyl compounds
GB201810668D0 (en) * 2018-06-28 2018-08-15 Stiftelsen Alzecure New compounds
EP3873474A4 (en) * 2018-10-30 2022-07-13 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS USED AS BET INHIBITORS
US11458149B1 (en) * 2019-05-31 2022-10-04 Ikena Oncology, Inc. TEAD inhibitors and uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024513606A (ja) * 2021-04-16 2024-03-26 オリオン コーポレーション Ｔｅａｄ阻害剤
JP7828367B2 (ja) 2021-04-16 2026-03-11 オリオン コーポレーション Ｔｅａｄ阻害剤
WO2024255856A1 (zh) * 2023-06-14 2024-12-19 赛诺哈勃药业（成都）有限公司 一种调控tead活性的化合物、其制备方法及其用途

Also Published As

Publication number Publication date
US20240124406A1 (en) 2024-04-18
WO2021247634A1 (en) 2021-12-09
AU2021283892A1 (en) 2023-02-02
CA3180846A1 (en) 2021-12-09
EP4164752A1 (en) 2023-04-19

Similar Documents

Publication Publication Date Title
JP7671293B2 (ja) 転写増強関連ドメイン（ｔｅａｄ）転写因子インヒビターおよびそれらの使用
US20240124406A1 (en) Inhibitors of transcriptional enhanced associate domain (tead) and uses thereof
US20220402869A1 (en) Transcriptional enhanced associate domain (tead) transcription factor inhibitors and uses thereof
JP7308146B2 (ja) インターロイキン１受容体関連キナーゼの阻害剤およびその使用
JP7258748B2 (ja) サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用
JP7472026B2 (ja) 選択的なタンパク質分解を誘導するための低分子およびその使用法
AU2019295632B2 (en) Taire family kinase inhibitors and uses thereof
JP2022529700A (ja) サイクリン依存性キナーゼ１２（ｃｄｋ１２）の分解剤およびその使用
US20220127284A1 (en) Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
JP7675070B2 (ja) 治療、特にｍｙｄ８８変異疾患における使用のためのｈｃｋ阻害剤としてのピラゾロピリミジン誘導体
AU2020301399B2 (en) HCK degraders and uses thereof
CA3012846A1 (en) Max binders as myc modulators and uses thereof
US20220242872A1 (en) E3 ligase binders and uses thereof
US20240360104A1 (en) Transcriptional enhanced associated domain (tead) transcription factor inhibitors and uses thereof
WO2022150768A1 (en) Yap-tead inhibitors and uses thereof
AU2019318046B2 (en) Histone demethylase 5 inhibitors and uses thereof
CN116761795A (zh) 转录增强关联结构域(tead)的抑制剂以及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240603

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250526

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250619